Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that 11 new programs entered clinical trials in 2025. These 11 ...

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics ...

Amphastar Pharmaceuticals entered an agreement with Nanjing Hanxin Pharmaceutical Technology for an exclusive license to develop and commercialize certain products with corticotropin compound. The ...

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 milli ...

Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potentialUp to ...

For settlers who arrived before the latest wave, watching the transformation unfold has been disorienting. 'Suddenly, Goa is ...

HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilitiesBEIJING, Jan. 12, ...

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first approved drug. The company received notice from the U.S. Food and Drug ...

In a detailed memorandum submitted by industry body NASSCOM, the sector has sought higher tax deductions for new employment, ...